CST 2032
Alternative Names: CST-2032Latest Information Update: 04 Mar 2024
At a glance
- Originator CuraSen Therapeutics
- Class Neuroprotectants
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cognition disorders
- No development reported Neurodegenerative disorders
Most Recent Events
- 01 Feb 2024 CuraSen Therapeutics completes a phase-II clinical trials in Cognition disorders in USA and New Zealand (PO, tablet) (NCT05104463)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in Belgium
- 28 Oct 2023 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in New Zealand